1. PD-016Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study. (2nd July 2019) Authors: Raimondi, A; Di Maio, M; Peverelli, G; Morano, F; Corallo, S; Bergamo, F; Cremolini, C; Smiroldo, V; Amatu, A; Tampellini, M; Fanchini, L; Murialdo, R; Clavarezza, M; Noventa, S; Adamo, V; Ratti, M; Petrelli, F; Antonuzzo, L; Palermo, M; de Braud, F Journal: Annals of oncology Issue: Volume 30(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 664PPhase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ). (23rd October 2018) Authors: Alsina, M; Varga, A; Amatu, A; Schellens, J H M; Witteveen, P O; Boni, V; Moreno, V; Bol, K; Lourbakos, A; Magin Ferrer, M; Wasserman, E Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗